Treatment groups were well balanced with respect to baseline demographics of strata history of PAH treatment and etiology of PAH, as well as the WHO Functional Class categories.The primary objective of the study was to compare sildenafil 80 mg TID versus 5 mg TID for mortality, with success defined by ruling out twice the mortality at 80 mg.The key secondary efficacy endpoint was time to first event of clinical worsening, defined as a composite endpoint of all-cause mortality, hospitalization for worsening PAH or disease progression.

• Sildenafil tablets are sometimes prescribed for conditions other than ED.
• The active ingredient aids in relaxing blood vessels in the body.
• White sildenafil tablets are often associated with certain pharmaceutical brands.
• Some countries have strict regulations on sildenafil distribution and sale.
• Sildenafil is typically not recommended for men with severe eyesight diseases.
• Adherence to prescribed guidelines optimizes treatment outcomes.
• The tablets are manufactured with quality control practices to ensure safety.
• Patients should avoid sudden changes in medication or dosage.
• Reactions to sildenafil can be immediate or delayed; monitor closely.
• Lifestyle factors like smoking can influence sildenafil’s effectiveness.
• Educate yourself on proper storage to maintain medication integrity.

An additional secondary endpoint was 6MWD at Months 6 and 12.Overall SurvivalAt the time of a planned interim analysis (50% deaths) it was identified that the primary efficacy objective of this protocol was met and therefore the study was stopped.

Images for AN 351

Treatment groups were well balanced with respect to baseline demographics of strata history of PAH treatment and etiology of PAH, as well as the WHO Functional Class categories.The primary objective of the study was to compare sildenafil 80 mg TID versus 5 mg TID for mortality, with success defined by ruling out twice the mortality at 80 mg.The key secondary efficacy endpoint was time to first event of clinical worsening, defined as a composite endpoint of all-cause mortality, hospitalization for worsening PAH or disease progression. An additional secondary endpoint was 6MWD at Months 6 and 12.Overall SurvivalAt the time of a planned interim analysis (50% deaths) it was identified that the primary efficacy objective of this protocol was met and therefore the study was stopped. Based on the primary efficacy endpoint (mortality), the non-inferiority of sildenafil 80 mg TID arm versus 5 mg TID arm was met using a 2-sided significance level of 0.003 for the interim analysis. Primary comparison of the 80 mg TID group to the 5 mg TID group yielded the HR (99.7% CI) = 0.51 (0.22, 1.21); i.e., non-inferiority was established.Table 6. Hazard Ratios for Overall Survival, Assessed in the Proportional Hazards Model – Intent To Treat Populationa.

Alcohol interaction warning

On treatment deaths: Any death within 7 days of last dose was regarded as “On treatment”, thus might include deaths occurred after discontinuation from study treatment.b. Hazard ratio estimates from the proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH.Kaplan-Meier estimates of survival at 3 years were 66%, 79%, and 85% in the 5-, 20-, and 80- mg TID dose groups, respectively.Clinical WorseningSildenafil 80 mg was also superior to 5 mg for time to first event of clinical worsening with HR (99.7% CI) = 0.44 (0.22, 0.89).Table 7. Hazard Ratios for Time to First Event of Clinical Worsening – Intent To Treat PopulationNote: Sildenafil 5 mg is not an approved dosage.Abbreviations: 6MWD = 6-minute walk distance; CI = confidence interval; PAH = pulmonary arterial hypertension.a. Clinical worsening events were defined as reduction from baseline in the 6MWD test by at least 15% and worsening functional class from baseline, both confirmed by a second test/evaluation within 2 weeks.b. Count of cases of disease progression as the first event of clinical worsening.c.

What are the most common side effects of sildenafil?

Count of non-elective hospital stays for worsening PAH as the first event of clinical worsening.d. Count of deaths as the first event of clinical worsening.e. Hazard ratio estimates from the proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH. P-value from the Wald test.6MWD at Months 6 and 12At baseline, the median of sildenafil citrate drug 6MWD for the intent-to-treat (ITT) population was 332 to 352 m. At Month 6, the median change from baseline was highest for sildenafil 80 mg TID with 28 m compared to 18 m and 19 m for sildenafil 5 mg TID and sildenafil 20 mg TID groups, respectively.The same was seen at Month 12, the median change from baseline for sildenafil 80 mg TID group was 33 m compared to 17 m for sildenafil 5 mg TID and 31 m in sildenafil 20 mg TID groups.Overall, the safety data for sildenafil 20 mg TID and for the higher sildenafil 80 mg TID dose were consistent with the established safety profile of sildenafil in previous adult PAH studies [see Adverse Reactions (6.1)].Pediatric use information is approved for Viatris Specialty LLC's, REVATIO (sildenafil) tablets. Based on the primary efficacy endpoint (mortality), the non-inferiority of sildenafil 80 mg TID arm versus 5 mg TID arm was met using a 2-sided significance level of 0.003 for the interim analysis.

• Sildenafil is classified as a prescription medication in most countries.
• Proper diagnosis of ED by a doctor is essential before using sildenafil.
• Sildenafil’s primary function is to facilitate normal erectile response.
• The drug's onset of action can vary among individuals.
• White sildenafil tablets are sometimes found in counterfeit markets.
• It’s advisable to start with the lowest effective dose.
• Some patients report a “refractory” period after taking sildenafil.
• Sildenafil should not be used with certain recreational drugs like poppers.
• The medication’s safety profile is well-understood when used correctly.
• Inform your healthcare provider if you experience prolonged erections.
• Keep an updated record of all medications while using sildenafil.

Primary comparison of the 80 mg TID group to the 5 mg TID group yielded the HR (99.7% CI) = 0.51 (0.22, 1.21); i.e., non-inferiority was established.Table 6. Hazard Ratios for Overall Survival, Assessed in the Proportional Hazards Model – Intent To Treat Populationa. On treatment deaths: Any death within 7 days of last dose was regarded as “On treatment”, thus might include deaths occurred after discontinuation from study treatment.b. Hazard ratio estimates from the proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH.Kaplan-Meier estimates of survival at 3 years were 66%, 79%, and 85% in the 5-, 20-, and 80- mg TID dose groups, respectively.Clinical WorseningSildenafil 80 mg was also superior to 5 mg for time to first event of clinical worsening with HR (99.7% CI) = 0.44 (0.22, 0.89).Table 7. Hazard Ratios for Time to First Event of Clinical Worsening – Intent To Treat PopulationNote: Sildenafil 5 mg is not an approved dosage.Abbreviations: 6MWD = 6-minute walk distance; CI = confidence interval; PAH = pulmonary arterial hypertension.a.

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	25mg	10 Pills	25.19€ 23.99€	Buy
Viagra Generic	200mg	90 + 6 Pills	170.79€ 162.66€	Buy
Kamagra	100mg	32 Pills	121.24€ 115.47€	Buy
Kamagra Soft Tabs	100mg	60 + 4 Pills	180.59€ 171.99€	Buy
Kamagra Polo	100mg	32 Pills	125.88€ 119.89€	Buy
Viagra Generic	50mg	20 Pills	40.52€ 38.59€	Buy
Kamagra Soft Tabs	100mg	32 Pills	120.11€ 114.39€	Buy
Viagra Generic	50mg	10 Pills	26.87€ 25.59€	Buy
Kamagra Oral Jelly	100mg	90 + 8 Sachets	303.56€ 289.10€	Buy
Viagra Generic	50mg	30 + 4 Pills	54.26€ 51.68€	Buy
Viagra Generic	150mg	90 + 6 Pills	147.18€ 140.17€	Buy
Viagra Generic	200mg	360 + 10 Pills	481.98€ 459.03€	Buy
Kamagra	100mg	12 Pills	55.64€ 52.99€	Buy
Kamagra Polo	100mg	12 Pills	60.21€ 57.34€	Buy
Kamagra Polo	100mg	120 + 6 Pills	327.15€ 311.57€	Buy
Viagra Generic	150mg	270 + 10 Pills	326.61€ 311.06€	Buy

Clinical worsening events were defined as reduction from baseline in the 6MWD test by at least 15% and worsening functional class from baseline, both confirmed by a second test/evaluation within 2 weeks.b. Count of cases of disease progression as the first event of clinical worsening.c. Count of non-elective hospital stays for worsening PAH as the first event of clinical worsening.d.

Sildenafil (Viagra) reviews

At the time of a planned interim analysis (50% deaths) it was identified that the primary efficacy objective of this protocol was met and therefore the study was stopped. Primary comparison of the 80 mg TID group to the 5 mg TID group yielded the HR (99.7% CI) = 0.51 (0.22, sildenafil citrate 200mg price 1.21); i.e., non-inferiority was established. Hazard Ratios for Overall Survival, Assessed in the Proportional Hazards Model – Intent To Treat Population On treatment deaths: Any death within 7 days of last dose was regarded as “On treatment”, thus might include deaths occurred after discontinuation from study treatment. Kaplan-Meier estimates of survival at 3 years were 66%, 79%, and 85% in the 5-, 20-, and 80- mg TID dose groups, respectively. Sildenafil 80 mg was also superior to 5 mg for time to first event of clinical worsening with HR (99.7% CI) = 0.44 (0.22, 0.89).

How sildenafil is used

Hazard Ratios for Time to First Event of Clinical Worsening – Intent To Treat Population Note: Sildenafil 5 mg is not an approved dosage. At baseline, the median of 6MWD for the intent-to-treat (ITT) population was 332 to 352 m. At Month 6, the median change from baseline was highest for sildenafil 80 mg TID with 28 m compared to 18 m and 19 m for sildenafil 5 mg TID and sildenafil 20 mg TID groups, respectively. The same was seen at Month 12, the median change from baseline for sildenafil 80 mg TID group was 33 m compared to 17 m for sildenafil 5 mg TID and 31 m in sildenafil 20 mg TID groups. Overall, the safety data for sildenafil 20 mg TID and for the higher sildenafil 80 mg TID dose were consistent with the established safety profile of sildenafil in previous adult PAH studies [see Adverse Reactions (6.1)].

What does Teva sildenafil do?

16 HOW SUPPLIED/STORAGE AND HANDLING Sildenafil 20 mg tablets USP are white to off-white, round biconvex film coated tablets debossed with '85' on one side and plain on other side.Bottles of 30 with child-resistant closure NDC 13668-185-30Bottles of 90 with child-resistant closure NDC 13668-185-90Bottles of 500 NDC 13668-185-05Bottles of 1000 NDC 13668-185-10Bottles of 5000 NDC 13668-185-51Recommended Storage for Sildenafil Tablets USP: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Sildenafil 20 mg tablets USP are white to off-white, round biconvex film coated tablets debossed with '85' on one side and plain on other side. Bottles of 30 with child-resistant closure NDC 13668-185-30 Bottles of 90 with child-resistant closure NDC 13668-185-90 Bottles of 500 NDC 13668-185-05 Bottles of 1000 NDC 13668-185-10 Bottles of 5000 NDC 13668-185-51 Recommended Storage for Sildenafil Tablets USP: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. 17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).• Inform patients of contraindication of sildenafil tablets with regular and/or intermittent use of organic nitrates.• Inform patients that sildenafil is also marketed as VIAGRA for erectile dysfunction. Advise patients taking sildenafil tablets not to take VIAGRA or other PDE-5 inhibitors.• Advise patients to seek immediate medical attention for a sudden loss of vision in one or both eyes while taking sildenafil tablets. Count of deaths as the first event of clinical worsening.e. Hazard ratio estimates from the proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH. P-value from the Wald test.6MWD at Months 6 and 12At baseline, the median of sildenafil citrate drug 6MWD for the intent-to-treat (ITT) population was 332 to 352 m. At Month 6, the median change from baseline was highest for sildenafil 80 mg TID with 28 m compared to 18 m and 19 m for sildenafil 5 mg TID and sildenafil 20 mg TID groups, respectively.The same was seen at Month 12, the median change from baseline for sildenafil 80 mg TID group was 33 m compared to 17 m for sildenafil 5 mg TID and 31 m in sildenafil 20 mg TID groups.Overall, the safety data for sildenafil 20 mg TID and for the higher sildenafil 80 mg TID dose were consistent with the established safety profile of sildenafil in previous adult PAH studies [see Adverse Reactions (6.1)].Pediatric use information is approved for Viatris Specialty LLC's, REVATIO (sildenafil) tablets. SUPER-1 (NCT00644605) - Sildenafil citrate Monotherapy [20 mg, 40 mg, and 80 mg Three Times a Day] A randomized, double-blind, placebo-controlled study of sildenafil citrate (SUPER-1) was conducted in 277 patients with PAH (defined as a mean pulmonary artery pressure≥25 mmHg at rest with a pulmonary capillary wedge pressure<15 mmHg). Patients were randomized to receive placebo (n=70) or sildenafil tablet 20 mg (n = 69), 40 mg (n = 67) or 80 mg (n = 71) three times a day for a period of 12 weeks. SUPER-2 (NCT00159887) Long-Term Treatment of PAH In a long-term follow-up of patients who were treated with sildenafil (n=277), K-M estimates of survival at 1, 2, and 3 years were 94%, 88% , and 79%, respectively.

TEVA 5343

SUPER-1 (NCT00644605) - Sildenafil citrate Monotherapy [20 mg, 40 mg, and 80 mg Three Times a Day] A randomized, double-blind, placebo-controlled study of sildenafil citrate (SUPER-1) was conducted in 277 patients with PAH (defined as a mean pulmonary artery pressure≥25 mmHg at rest with a pulmonary capillary wedge pressure<15 mmHg). Patients were randomized to receive placebo (n=70) or sildenafil tablet 20 mg (n = 69), 40 mg (n = 67) or 80 mg (n = 71) three times a day for a period of 12 weeks. SUPER-2 (NCT00159887) Long-Term Treatment of PAH In a long-term follow-up of patients who were treated with sildenafil (n=277), K-M estimates of survival at 1, 2, and 3 years were 94%, 88% , and 79%, respectively. At baseline patients had PPH (80%) or PAH secondary to CTD (20%);WHO Functional Class I (1%), II (26%), III (67%), or IV (6%); and the mean age was 48 years, 80% were female, and 79% were Caucasian. The mean change from baseline at Week 16 (last observation carried forward) was 30 meters for the sildenafil tablet group compared with 4 meters for the placebo group giving an adjusted treatment difference of 26 meters (95% CI: 10.8, 41.2) (p = 0.0009).

Sildenafil vs. tadalafil

A mean placebo-corrected treatment effect of -3.9 mmHg was observed in favor of sildenafil tablet (95% CI: -5.7, -2.1) (p = 0.00003). Kaplan- Meier plot of time to clinical worsening is presented in Figure 5. Kaplan-Meier Plot of Time (in Days) to Clinical Worsening of PAH in PACES-1 Improvements in WHO Functional Class for PAH were also demonstrated in patients on sildenafil tablet compared to placebo. Study A1481243 (NCT00323297) – Sildenafil citrate Added to Bosentan Therapy – Lack of Effect on Exercise Capacity A randomized, double-blind, placebo-controlled study was conducted in 103 patients with PAH who were on bosentan therapy for a minimum of 3 months. Study A1481324 (NCT02060487) - Study to Assess the Effects of Sildenafil on Mortality in Adults with PAH A study to assess the effects of multiple doses of sildenafil on mortality in adults with PAH was conducted following the observation of a higher risk of mortality in pediatric patients taking a high dose of sildenafil TID, based on body weight, compared to those taking a lower dose of sildenafil in the long-term extension of the pediatric clinical trial.

Clinical monitoring

The study was a randomized, double-blind, parallel-group study in 385 adults with PAH. Treatment groups were well balanced with respect to baseline demographics of strata history of PAH treatment and etiology of PAH, as well as the WHO Functional Class categories. The primary objective of the study was to compare sildenafil 80 mg TID versus 5 mg TID for mortality, with success defined by ruling out twice the mortality at 80 mg. The key secondary efficacy endpoint was time to first event of clinical worsening, defined as a composite endpoint of all-cause mortality, hospitalization for worsening PAH or disease progression. An additional secondary endpoint was 6MWD at Months 6 and 12. At baseline patients had PPH (80%) or PAH secondary to CTD (20%);WHO Functional Class I (1%), II (26%), III (67%), or IV (6%); and the mean age was 48 years, 80% were female, and 79% were Caucasian. The mean change from baseline at Week 16 (last observation carried forward) was 30 meters for the sildenafil tablet group compared with 4 meters for the placebo group giving an adjusted treatment difference of 26 meters (95% CI: 10.8, 41.2) (p = 0.0009). A mean placebo-corrected treatment effect of -3.9 mmHg was observed in favor of sildenafil tablet (95% CI: -5.7, -2.1) (p = 0.00003). Kaplan- Meier plot of time to clinical worsening is presented in Figure 5. Kaplan-Meier Plot of Time (in Days) to Clinical Worsening of PAH in PACES-1 Improvements in WHO Functional Class for PAH were also demonstrated in patients on sildenafil tablet compared to placebo. Study A1481243 (NCT00323297) – Sildenafil citrate Added to Bosentan Therapy – Lack of Effect on Exercise Capacity A randomized, double-blind, placebo-controlled study was conducted in 103 patients with PAH who were on bosentan therapy for a minimum of 3 months. Study A1481324 (NCT02060487) - Study to Assess the Effects of Sildenafil on Mortality in Adults with PAH A study to assess the effects of multiple doses of sildenafil on mortality in adults with PAH was conducted following the observation of a higher risk of mortality in pediatric patients taking a high dose of sildenafil TID, based on body weight, compared to those taking a lower dose of sildenafil in the long-term extension of the pediatric clinical trial. The study was a randomized, double-blind, parallel-group study in 385 adults with PAH. Treatment groups were well balanced with respect to baseline demographics of strata history of PAH treatment and etiology of PAH, as well as the WHO Functional Class categories.

• Sildenafil tablets are available in various generic versions.
• White sildenafil tablets are often easier to swallow due to their shape.
• The cost of sildenafil varies depending on the brand and dosage.
• Using sildenafil responsibly can improve quality of life for users.
• Not all erectile issues require medication; consult a doctor for underlying causes.
• Sildenafil is not suitable for women or children.
• The drug works by blocking PDE5, enhancing natural erections.
• Physical activity after taking sildenafil can enhance its effectiveness.
• Sildenafil is sometimes used off-label for pulmonary hypertension.
• Proper hydration may help reduce side effects like headaches.
• Patients should report any persistent or severe side effects to a healthcare professional.

The primary objective of the study was to compare sildenafil 80 mg TID versus 5 mg TID for mortality, with success defined by ruling out twice the mortality at 80 mg. The key secondary efficacy endpoint was time to first event of clinical worsening, defined as a composite endpoint of all-cause mortality, hospitalization for worsening PAH or disease progression. An additional secondary endpoint was 6MWD at Months 6 and 12. At the time of a planned interim analysis (50% deaths) it was identified that the primary efficacy objective of this protocol was met and therefore the study was stopped. Primary comparison of the 80 mg TID group to the 5 mg TID group yielded the HR (99.7% CI) = 0.51 (0.22, sildenafil citrate 200mg price 1.21); i.e., non-inferiority was established. Hazard Ratios for Overall Survival, Assessed in the Proportional Hazards Model – Intent To Treat Population On treatment deaths: Any death within 7 days of last dose was regarded as “On treatment”, thus might include deaths occurred after discontinuation from study treatment. Kaplan-Meier estimates of survival at 3 years were 66%, 79%, and 85% in the 5-, 20-, and 80- mg TID dose groups, respectively. Sildenafil 80 mg was also superior to 5 mg for time to first event of clinical worsening with HR (99.7% CI) = 0.44 (0.22, 0.89). Hazard Ratios for Time to First Event of Clinical Worsening – Intent To Treat Population Note: Sildenafil 5 mg is not an approved dosage. At baseline, the median of 6MWD for the intent-to-treat (ITT) population was 332 to 352 m.

The bottom line

Such an event may be a sign of NAION.• Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking sildenafil tablets. These events may be accompanied by tinnitus and dizziness.Trademarks are the property of their respective owners.Manufactured by:Torrent Pharmaceuticals LTD., India.Manufactured for:Torrent Pharma INC., Basking Ridge, NJ 07920.8110130 Revised: May 2026 Advise the patient to read the FDA-approved patient labeling (Patient Information).

Your expert team

At Month 6, the median change from baseline was highest for sildenafil 80 mg TID with 28 m compared to 18 m and 19 m for sildenafil 5 mg TID and sildenafil 20 mg TID groups, respectively. The same was seen at Month 12, the median change from baseline for sildenafil 80 mg TID group was 33 m compared to 17 m for sildenafil 5 mg TID and 31 m in sildenafil 20 mg TID groups. Overall, the safety data for sildenafil 20 mg TID and for the higher sildenafil 80 mg TID dose were consistent with the established safety profile of sildenafil in previous adult PAH studies [see Adverse Reactions (6.1)]. 16 HOW SUPPLIED/STORAGE AND HANDLING Sildenafil 20 mg tablets USP are white to off-white, round biconvex film coated tablets debossed with '85' on one side and plain on other side.Bottles of 30 with child-resistant closure NDC 13668-185-30Bottles of 90 with child-resistant closure NDC 13668-185-90Bottles of 500 NDC 13668-185-05Bottles of 1000 NDC 13668-185-10Bottles of 5000 NDC 13668-185-51Recommended Storage for Sildenafil Tablets USP: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Sildenafil 20 mg tablets USP are white to off-white, round biconvex film coated tablets debossed with '85' on one side and plain on other side.

2. Can you get generic Viagra online?

Bottles of 30 with child-resistant closure NDC 13668-185-30 Bottles of 90 with child-resistant closure NDC 13668-185-90 Bottles of 500 NDC 13668-185-05 Bottles of 1000 NDC 13668-185-10 Bottles of 5000 NDC 13668-185-51 Recommended Storage for Sildenafil Tablets USP: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. 17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).• Inform patients of contraindication of sildenafil tablets with regular and/or intermittent use of organic nitrates.• Inform patients that sildenafil is also marketed as VIAGRA for erectile dysfunction.

Precaution/Contraindication	Description	Notes
Nitrate use	Do not take with nitrates for chest pain	Risk of severe hypotension
Heart conditions	Consult a doctor if you have cardiovascular issues	Risk of adverse cardiovascular events
Liver or kidney impairment	Reduced dosing may be necessary	Altered drug metabolism
Drug interactions	Combine with caution; may interact with other meds	Always consult a healthcare provider

Advise patients taking sildenafil tablets not to take VIAGRA or other PDE-5 inhibitors.• Advise patients to seek immediate medical attention for a sudden loss of vision in one or both eyes while taking sildenafil tablets. Such an event may be a sign of NAION.• Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking sildenafil tablets. These events may be accompanied by tinnitus and dizziness.Trademarks are the property of their respective owners.Manufactured by:Torrent Pharmaceuticals LTD., India.Manufactured for:Torrent Pharma INC., Basking Ridge, NJ 07920.8110130 Revised: May 2026 Advise the patient to read the FDA-approved patient labeling (Patient Information).